Search
+
    SEARCHED FOR:

    DIABETES TREATMENT

    Beware of weight loss medications; they can make you go blind

    A recent study conducted by researchers at Massachusetts Eye and Ear hospital has found a significant link between popular weight loss drugs containing semaglutide and an increased risk of Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION), a rare condition causing sudden vision loss in one eye. The study, published in JAMA Ophthalmology, revealed that obese patients using these medications were over seven times more likely to develop NAION, while diabetic patients faced more than four times the risk.

    Living with diabetes: A holistic approach

    Combatting diabetes through weight loss is key for reducing risks of heart disease and stroke, emphasizing holistic lifestyle management.

    India to make drugs for diabetes, obesity under PLI by 2026, says report

    India plans to incentivize local manufacturing of GLP-1 drugs, crucial for treating diabetes and obesity, starting in 2026, as per a government official speaking to Reuters. These drugs, originally approved for diabetes treatment, are also used for obesity due to their ability to slow digestion and reduce appetite. Novo Nordisk's patent on semaglutide, a key ingredient in popular drugs like Wegovy and Ozempic, is set to expire in India by 2026. Indian companies are already preparing to manufacture these drugs under the government's production-linked incentive (PLI) scheme.

    Diabetes management made easier: Your guide to a healthier lifestyle

    Proactively collaborating with healthcare professionals for personalized strategies enhances diabetes management, leading to improved overall well-being and better health outcomes.

    Biocon seeks partner to test generic Wegovy, Ozempic in China

    India's Biocon is seeking a Chinese partner to conduct clinical trials on generic versions of Novo Nordisk's popular diabetes drug Ozempic and weight loss treatment Wegovy. Biocon aims to eventually launch these generics globally, with plans to find a partner for the trials on over 500 patients in China, citing the substantial investment required. The move comes ahead of the patent protection expiry on key ingredients in the drugs in 2026.

    Ozempic: Bengaluru is the secret ingredient behind the wonder weight loss drugs' success

    Novo Nordisk's India team played a pivotal role in the success of Ozempic, a semaglutide-based drug for diabetes and weight management. The Bengaluru-based Global Business Services unit collaborated on clinical trials and biostatistics. Despite global demand, Ozempic's availability in India remains uncertain due to supply challenges, with significant hiring planned to bolster Novo Nordisk's workforce in India.

    The Economic Times
    BACK TO TOP